Licenses, Phase III Trial Initiation and Results, and Investments - Research Report on Johnson & Johnson, Sanofi, AstraZeneca, Novartis, and GSK

NEW YORK, August 14, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Sanofi SA (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On August 8, 2013, Johnson & Johnson's Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved VELCADE (bortezomib) as an induction therapy in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD). According to the Company, the license extension applies to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation. Further, Janssen noted that the approval by the EC was based on the analysis of data from two Phase III trials which demonstrated that treatment with VELCADE-based induction improved post-induction and post-transplant response rates as well as progression-free survival (PFS). The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Sanofi SA Research Report

On August 5, 2013, Sanofi Pasteur, the vaccines division of Sanofi SA (Sanofi), announced the initiation of its Phase III clinical program, Cdiffense, to assess the safety, immunogenicity, and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). According to the Company, the investigational vaccine aims to protect at-risk individuals from C. diff, which is reported to be emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide. The Company added that the vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria. Further, Sanofi Pasteur noted that the Cdiffense Phase III clinical program has recently started recruiting volunteers for a randomized, observer-blind, placebo-controlled, multi-center, multi-national trial. The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/29ea_SNY]

--

AstraZeneca PLC Research Report

On August 1, 2013, AstraZeneca PLC (AstraZeneca) reported Q2 2013 financial results. The Company's revenue for Q2 2013 was $6.2 billion, down 6.4% YoY. Core EPS for Q2 2013 stood at $1.20, compared with $1.57 per share in Q2 2012. According to the Company, revenue impact from products that have recently lost exclusivity has moderated to around $500 million, less than half of the impact seen in Q1 2013. Further, the Company reported a 4% YoY increase in the rest of the portfolio revenue attributable to a double-digit increase from the five growth platforms. AstraZeneca also announced the addition of three late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases. "We have made real progress in the second quarter against our strategic priorities despite the anticipated impact on revenue of the loss of exclusivity for some brands," said Pascal Soriot, CEO of AstraZeneca. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]

--

Novartis AG Research Report

On August 7, 2013, Novartis AG (Novartis) announced that its global Phase III study demonstrated that Afinitor (everolimus) was not able to extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or intolerance to sorafenib. The Company added that it will not proceed with regulatory filings of Afinitor in this indication. However, Novartis noted that the results of the HCC trial will not impact the worldwide approval of Afinitor for other indications such as hormone receptor positive advanced breast cancer, advanced pancreatic neuroendocrine tumors, and advanced renal cell carcinoma. According to Novartis, Everolimus is also in Phase III development for other diseases, and the results of the trials are expected in 2014 and 2015. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

--

GlaxoSmithKline plc Research Report

On August 8, 2013, GlaxoSmithKline plc (GSK) announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture fund that will invest in companies that pioneer bioelectronics medicines and technologies. The Company added that the fund's first investment will be in SetPoint Medical, a California company involved in creating implantable devices to treat inflammatory diseases. "We want to help create the medicines of the future and be the catalyst for this work," said Moncef Slaoui, Chairman of R&D and Architect of GSK's early stage investment strategy. "GSK can play the integrating role that is needed to drive this new of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts." APVC intends to build a portfolio of five to seven companies over the next five years. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner